ClinicalTrials.gg
CompletedNCT05527106Updated Sep 2, 2022

Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma

An interventional study of Citicoline and Docosahexaenoic Acid (DHA) in Glaucoma, sponsored by Institut Catala de Retina. Completed at 1 site in Spain. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Institut Catala de Retina · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 7 years 5 months after the study started (first participant enrolled Mar 2015, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.

Enrollment
21st of 33
73 · median 100
Started
2015
with 1 other
No phase
16 of 43
3 open now
Registered
36th of 43
by date
Lead sponsor
3 of 43
Institut Catala de Retina

Among the 43 studies in Glaucoma with a site in Spain, this one is the 21st largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 with no phase, and was the 36th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma with a site in Spain, or all of them as a file.
02

Study summary

Pilot, single-blind, randomized and controlled study to evaluate the changes produced in the visual function of patients with glaucoma after oral administration for 3 months of citicoline and docosahexaenoic Acid (DHA) vs citicoline and docosahexaenoic Acid (DHA) vs vitamin C.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • nutraceuticals
  • dha (docosahexaenoic acid)
  • citicoline
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with chronic, primary or secondary, open or closed angle glaucoma, diagnosed by meeting the following criteria:

    • Signs of structural damage: thinning of the optical nerve or peripapillary hemorrhage or decrease in the nerve fiber layer that can be seen by OCT.
    • Signs of functional damage: 3 points outside 95% of the normal limit on the visual field pattern deviation graph.
  2. There must be at least 3 reliable visual fields prior to the start of the study.
  3. Patients between 50 and 75 years old, homogeneously distributed among the groups.
  4. Glaucoma with functional and structural damage.

    • Medium grade, Mean Deviation (MD) between -4 and -20 dB.
    • In at least one eye.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with some other vitamin or nutraceutical preparation.
  2. Any pathology that can alter the visual field. (Neurological diseases, retinopathies, advanced cataract, patients treated with lyrica (due to the affectation it produces in the visual field)).
  3. to aspirin. (Cross-allergic reaction has been reported in patients taking citicoline.)
  4. Allergic to fish protein.
  5. Eye surgery in the 3 months before or during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Citicoline

    Cebrolux 800 is a food supplement based on citicoline (163 mg) that also contains vitamin A, E, C and B6.

    Dietary Supplement: Citicoline

  • Experimental
    Docosahexaenoic Acid (DHA)

    Brudypio 1.5g is a food supplement based on Omega-3 fatty acid in the form of triglycerides (DHA 70% \[350 mg\], EPA 8.5%, DPA 6%) that also contains vitamins (A, B1, B2, B3, B6, B9, B12, C, E), carotenoids ( lutein, zeaxanthin, lycopene), glutathione, coenzyme Q10 and minerals (Zn, Se, Cu, Mn).

    Dietary Supplement: Docosahexaenoic Acid (DHA)

  • Experimental
    Citicoline and Docosahexaenoic Acid (DHA)

    Cebrolux 800 and Brudypio 1.5g (see above).

    Dietary Supplement: Citicoline and Docosahexaenoic Acid (DHA)

  • Experimental
    Vitamin C

    Vitamin C.

    Dietary Supplement: Vitamin C

Interventions

06

What researchers measure

Primary outcomes

  1. Effect on Mean Defect (MD)

    Evaluation of changes on the MD (decibels) with study treatment.

    Time frame: From Baseline to Month 3.

  2. Effect on Visual Field Index (VFI)

    Evaluation of changes on the VFI (%) with study treatment.

    Time frame: From Baseline to Month 3.

Secondary outcomes

  1. Evaluation of the changes produced in the intraocular pressure (IOP)

    To compare IOP (mmHg) measurements with study treatment.

    Time frame: From Baseline to Month 3.

  2. Evaluation of tolerance

    Describe the tolerance and the adverse events with study treatment.

    Time frame: From Month 1 to Month 3

07

Study locations

1 site
  • Institut Catala de Retina
    Barcelona, 08022, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in May 2022, 86 months.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 86 months is above that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Sep 2, 2022
StartActual
Mar 12, 2015
Primary completionActual
May 25, 2022
CompletionActual
May 25, 2022
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05527106
Lead sponsor
Institut Catala de Retina
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Mar 12, 2015
Primary completion
May 25, 2022
Completion
May 25, 2022
Last update
Sep 2, 2022

Study contacts

Alfonso Anton, MD, PhD
principal investigator · Institut Catala de Retina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cytidine Diphosphate Choline · Docosahexaenoic Acids · Ascorbic Acid

Start the discussion